tetano
Editor, Senior Moderator
Cureus
. 2022 Jan 6;14(1):e20979.
doi: 10.7759/cureus.20979. eCollection 2022 Jan.
COVID-19 Vaccine-Induced Pneumonitis, Myositis and Myopericarditis
Mariya Farooq[SUP] 1 [/SUP], Yaser Mohammed[SUP] 2 [/SUP], Mansoor Zafar[SUP] 3 [/SUP], Dawpadee Dharmasena[SUP] 2 [/SUP], Usman Iqbal Rana[SUP] 2 [/SUP], Osei Kankam[SUP] 4 [/SUP]
Affiliations
Abstract
A 63-year-old male, with no significant past history and not on any regular medications previously, had mild respiratory symptoms post the first dose of the AstraZeneca (Cambridge, England) coronavirus disease 2019 (COVID-19) vaccine, which were self-limiting. Following the second dose of the vaccine, he arrived at the emergency department (ED) with worsening shortness of breath. During this admission, he was assumed to have interstitial lung disease due to a possible past history of occupational exposure. He responded to a short-term course of corticosteroids and antibiotics and was discharged home. However, he reported again to the emergency department three weeks later, with persistent dyspnoea along with myalgia. His blood tests and imaging from scans suggested myositis, pneumonitis, and myopericarditis. Since he recently had the COVID-19 AstraZeneca vaccine, it was postulated as the most likely cause of the symptoms. He was managed with intravenous (IV) corticosteroids followed by oral corticosteroids with symptom resolution.
Keywords: covid 19; covid-19 myopericarditis; covid-19 myositis; covid-19 pneumonitis; mri cardiac.
. 2022 Jan 6;14(1):e20979.
doi: 10.7759/cureus.20979. eCollection 2022 Jan.
COVID-19 Vaccine-Induced Pneumonitis, Myositis and Myopericarditis
Mariya Farooq[SUP] 1 [/SUP], Yaser Mohammed[SUP] 2 [/SUP], Mansoor Zafar[SUP] 3 [/SUP], Dawpadee Dharmasena[SUP] 2 [/SUP], Usman Iqbal Rana[SUP] 2 [/SUP], Osei Kankam[SUP] 4 [/SUP]
Affiliations
- PMID: 35004093
- PMCID: PMC8733846
- DOI: 10.7759/cureus.20979
Abstract
A 63-year-old male, with no significant past history and not on any regular medications previously, had mild respiratory symptoms post the first dose of the AstraZeneca (Cambridge, England) coronavirus disease 2019 (COVID-19) vaccine, which were self-limiting. Following the second dose of the vaccine, he arrived at the emergency department (ED) with worsening shortness of breath. During this admission, he was assumed to have interstitial lung disease due to a possible past history of occupational exposure. He responded to a short-term course of corticosteroids and antibiotics and was discharged home. However, he reported again to the emergency department three weeks later, with persistent dyspnoea along with myalgia. His blood tests and imaging from scans suggested myositis, pneumonitis, and myopericarditis. Since he recently had the COVID-19 AstraZeneca vaccine, it was postulated as the most likely cause of the symptoms. He was managed with intravenous (IV) corticosteroids followed by oral corticosteroids with symptom resolution.
Keywords: covid 19; covid-19 myopericarditis; covid-19 myositis; covid-19 pneumonitis; mri cardiac.